PCI与冠状动脉旁路移植术治疗三支或左主干冠状动脉病变:多中心随机对照SYNTAX试验10年随访
SYNTAXES研究是对多中心随机对照SYNTAX试验的10年随访扩展,纳入1800例de-novo三支或左主干冠状动脉病变患者,1:1随机分至PCI组(使用第一代紫杉醇洗脱支架,n=903)或CABG组(n=897)。10年时PCI组248例(28%)死亡,CABG组212例(24%)死亡(HR 1.19,95%CI 0.99-1.43,p=0.066),无显著差异。三支病变亚组中PCI死亡153/546(28%),CABG死亡114/549(21%)(HR 1.42,95%CI 1.11-1.81),CABG有显著生存获益;左主干病变亚组PCI死亡95/357(27%),CABG死亡98/348(28%)(HR 0.92,95%CI 0.69-1.22),无显著差异,亚组交互作用p=0.023。糖尿病亚组无交互作用(p=0.60),SYNTAX评分三分位无线性趋势(p=0.20)。
要点
- 10年全因死亡:PCI组28% vs CABG组24%,HR 1.19(95%CI 0.99-1.43),p=0.066,无显著差异。
- 三支病变亚组:PCI死亡28% vs CABG 21%,HR 1.42(95%CI 1.11-1.81),CABG有显著生存获益。
- 左主干病变亚组:PCI死亡27% vs CABG 28%,HR 0.92(95%CI 0.69-1.22),无显著差异;亚组交互作用p=0.023。
- 糖尿病亚组无治疗交互作用(p=0.60),SYNTAX评分三分位无线性趋势(p=0.20)。
- 研究使用第一代紫杉醇洗脱支架,结论不能直接外推至当代PCI技术。
适用人群与场景
- de-novo三支或左主干冠状动脉病变患者,来自18个北美和欧洲国家85家医院。
- 排除有PCI或CABG史、急性心肌梗死、或需同期心脏手术指征的患者。
研究设计与关键结果
- 多中心随机对照试验的10年随访扩展(SYNTAXES),1800例患者1:1随机至PCI组(n=903,第一代紫杉醇洗脱支架)或CABG组(n=897)。
- 10年全因死亡:PCI组248/903(28%)vs CABG组212/897(24%),HR 1.19(95%CI 0.99-1.43),p=0.066。
- 三支病变亚组:PCI组153/546(28%)vs CABG组114/549(21%),HR 1.42(95%CI 1.11-1.81)。
- 左主干病变亚组:PCI组95/357(27%)vs CABG组98/348(28%),HR 0.92(95%CI 0.69-1.22),亚组交互作用p=0.023。
- 糖尿病亚组无治疗交互作用(p=0.60),SYNTAX评分三分位无线性趋势(p=0.20)。
证据类型、等级与局限
- 证据类型:多中心随机对照试验的10年随访扩展研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于三支病变患者,10年随访数据支持CABG较第一代紫杉醇洗脱支架PCI有生存获益(HR 1.42,95%CI 1.11-1.81)。
- 对于左主干病变患者,PCI与CABG的10年全因死亡无显著差异(HR 0.92,95%CI 0.69-1.22)。
- 该研究结果基于第一代紫杉醇洗脱支架,不能直接外推至当代PCI技术。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial was a non-inferiority trial that compared percutaneous coronary intervention (PCI) using first-generation paclitaxel-eluting stents with coronary artery bypass grafting (CABG) in patients with de-novo three-vessel and left main coronary artery disease, and reported results up to 5 years. We now report 10-year all-cause death results.
METHODS: The SYNTAX Extended Survival (SYNTAXES) study is an investigator-driven extension of follow-up of a multicentre, randomised controlled trial done in 85 hospitals across 18 North American and European countries. Patients with de-novo three-vessel and left main coronary artery disease were randomly assigned (1:1) to the PCI group or CABG group. Patients with a history of PCI or CABG, acute myocardial infarction, or an indication for concomitant cardiac surgery were excluded. The primary endpoint of the SYNTAXES study was 10-year all-cause death, which was assessed according to the intention-to-treat principle. Prespecified subgroup analyses were performed according to the presence or absence of left main coronary artery disease and diabetes, and according to coronary complexity defined by core laboratory SYNTAX score tertiles. This study is registered with ClinicalTrials.gov, NCT03417050.
FINDINGS: From March, 2005, to April, 2007, 1800 patients were randomly assigned to the PCI (n=903) or CABG (n=897) group. Vital status information at 10 years was complete for 841 (93%) patients in the PCI group and 848 (95%) patients in the CABG group. At 10 years, 248 (28%) patients had died after PCI and 212 (24%) after CABG (hazard ratio 1·19 [95% CI 0·99-1·43], p=0·066). Among patients with three-vessel disease, 153 (28%) of 546 had died after PCI versus 114 (21%) of 549 after CABG (hazard ratio 1·42 [95% CI 1·11-1·81]), and among patients with left main coronary artery disease, 95 (27%) of 357 had died after PCI versus 98 (28%) of 348 after CABG (0·92 [0·69-1·22], pinteraction=0·023). There was no treatment-by-subgroup interaction with diabetes (pinteraction=0·60) and no linear trend across SYNTAX score tertiles (ptrend=0·20).
INTERPRETATION: At 10 years, no significant difference existed in all-cause death between PCI using first-generation paclitaxel-eluting stents and CABG. However, CABG provided a significant survival benefit in patients with three-vessel disease, but not in patients with left main coronary artery disease.
FUNDING: German Foundation of Heart Research (SYNTAXES study, 5-10-year follow-up) and Boston Scientific Corporation (SYNTAX study, 0-5-year follow-up).
参考来源
- Thuijs DJFM, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet. 2019. PMID: 31488373. doi:10.1016/S0140-6736(19)31997-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。